Ignite Creation Date:
2024-05-06 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04715750
Status:
COMPLETED
Last Update Posted:
2024-05-13
First Post:
2020-12-11
Brief Title:
Evaluation of Imaging Characteristics of 18FPI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
Sponsor:
Life Molecular Imaging GmbH
Organization:
Life Molecular Imaging SA
Study Overview
Official Title:
An Open Label Single Center Study to Evaluate the Safety and Imaging Characteristics of 18FPI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimers Disease AD and Patients With Progressive Supranuclear Palsy PSP After iv Application of 18FPI-2620 With High and Low Specific Activity
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label study without randomisation All eligible patients will receive two administrations of the investigational imaging agent 18FPI-2620 at a radioactive dose of 185 MBq one with high specific activity 5 µg tracer mass dose another one with low specific activity 40-50 µg tracer mass dose
Detailed Description:
This is an open-label single center study to visually assess and quantitatively compare brain PET images obtained after application of 18FPI-2620 with different specific activities 1 High specific activity low mass dose 185 MBq containing a maximum mass dose of 5 μg in up to 10 mL and 2 Low specific activity high mass dose 185 MBq containing a maximum mass dose of 40-50 μg in up to 10 mL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None